Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Short Interest Update

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) was the target of a significant increase in short interest in March. As of March 15th, there was short interest totalling 779,800 shares, an increase of 35.9% from the February 28th total of 573,800 shares. Approximately 0.2% of the shares of the stock are short sold. Based on an average trading volume of 100 shares, the days-to-cover ratio is presently 7,798.0 days.

Analysts Set New Price Targets

Separately, Barclays upgraded Swedish Orphan Biovitrum AB (publ) to a “strong-buy” rating in a research report on Wednesday, January 8th.

Swedish Orphan Biovitrum AB (publ) Stock Performance

OTCMKTS:BIOVF opened at $28.75 on Wednesday. Swedish Orphan Biovitrum AB has a twelve month low of $22.87 and a twelve month high of $32.25. The company has a market cap of $10.24 billion, a P/E ratio of 27.64 and a beta of 0.62. The company has a current ratio of 0.91, a quick ratio of 0.62 and a debt-to-equity ratio of 0.31. The company’s 50-day moving average price is $29.64 and its 200-day moving average price is $29.51.

Swedish Orphan Biovitrum AB (publ) Company Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.